MONTPELLIER, France, May 19, 2016 (GLOBE NEWSWIRE) -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, today announced the first surgical operation with the ROSA™ Spine in Spain. The procedure, which was performed at Hospital La Fe of Valencia, treated a patient with degenerative disc disease.
Degenerative disc disease is a condition in which pain is caused from a damaged spinal disc, most often as a result of aging. The operation, which consists of fusing lumbar vertebrae to reduce back pain, was performed on a 47 year-old patient by Dr. Carlos Botella, a neurosurgeon at La Fe Hospital of Valencia (Spain). La Fe is a University-based Hospital that is recognized as a leading European facility for the treatment of brain and spine pathologies.
“ROSA™ Spine allows us to perform minimally invasive surgical interventions that track and adjust for the patient’s body movements during the procedure. As a result, we have increased confidence that the instrument and implant positioning is aligned with the planned trajectory, facilitating a highly accurate outcome," said Dr. Carlos Botella, a neurosurgeon specializing in the treatment of neurological and spinal disorders.
Bertin Nahum, CEO and founder of Medtech, commented, “There is increasing interest in robotically assisted, minimally-invasive spine surgery and we are pleased with the continued expansion of our ROSA™ Spine system in the marketplace. Patients in Spain now have access to our innovative robotic technology for spine surgery and I would like to thank La Fe Hospital for contributing to the advancement of minimally invasive techniques. This procedure also highlights the growing adoption of our robotic technology for neurological and spinal procedures by leading surgical teams throughout Europe.”
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 email@example.com PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 firstname.lastname@example.org Joanna Zimmerman (US) Tel : +1 646-536-7006 email@example.com